Prospects for hepatitis C vaccine

Acta Virologica

Volumn 48, Issue 4, 2004, Pages 215-221

  Bhopale, G M ^a   Nanda, R K ^a  

^a Hindustan Antibiotics Ltd   (India)

Author keywords

Hepatitis C virus; Protective immune response; Vaccine

Indexed keywords

AS 01 B; BACTERIAL VACCINE; CPG 10105; DNA VACCINE; HEPATITIS C VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; HEPATITIS VACCINE;

ADJUVANT THERAPY; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMORAL IMMUNITY; NONHUMAN; REVIEW; HUMAN; IMMUNOLOGY; VIRION;

HEPATITIS C VIRUS;

HEPACIVIRUS; HUMANS; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES; VIRION;

EID: 15544372850     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Arribillaga L, de Cerio AL, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-Romero O, Borras-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J, Lasarte JJ (2002): Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV recombinant vaccinia virus. Vaccine 21, 202-210.
2. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, Lanford RE (2001): Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33, 1479-1487.
3. Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, Greenberg HB, Ito S, Liang TJ (1999): Hepatitis C virus like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 117, 1397-1407.
4. Bellentani S, Tiribelli C (2001): The spectrum of liver disease in the general population. Lesson from the Dionysos study. J. Hepatol. 35, 531-537.
5. Boyer N, Marcellin P (2000): Pathogenesis, diagnosis and management of hepatitis C. J. Hepatol. 32, 98-112.
6. Brinster C, Inchauspe G (2001): DNA vaccines for hepatitis C virus. Intervirology 44, 143-153.
7. Brinster C, Chen M, Boucreux D, Paranhos-Baccala G, Liljestrom P, Lemmonier F, Inchauspe G (2002): Hepatitis C virus non-structural protein 3 specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. 83, 369-381.
8. Brunna-Romero O, Lasarte JJ, WillKinson G, Grace K, Clarke B, Borras-Cuesta F, Prieto J (1997): Induction of cytotoxic T cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 25, 470-477.
9. Bukh J, Miller RH, Purcell RH (1995): Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin. Liver Dis. 15, 41-63.
10. Buonocore L, Blight KJ, Rice CM, Rose JK (2002): Characterization of Vesicular stomatis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol. 76, 6865-6872.
11. Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L, Birkett A, Peterson D, Milich D (1999): Limited humoral immunity in hepatitis C virus infection. Gastroenterology 116, 135-143.
12. Chen KM (2003): Immunopathogenesis of hepatitis C virus infection Clin. Liver Dis. 1, 89-105.
13. Cho JH, Lee SW, Sung YC (1999): Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage colony stimulating factor gene in intramuscular DNA immunization. Vaccine 17, 1136-1144.
14. Clarke B (1997): Molecular virology of hepatitis C virus. J. Gen. Virol. 78, 2379-2410.
15. Cohen J (1999): The scientific challenge of hepatitis C. Science 285, 26-30.
16. Duenas-Carrera S, Vina A, Martinez R, Alvarez-Lajonchere L, Alvarez-Obregon JC, Marante J, Perez A, Mosqueda O, Martinez G, Morales J (2004): Immunization with a DNA vaccine encoding the hepatitis C virus structural antigens elicits specific immune response against the capsid and envelope proteins in rabbits and macaques iras. Biotechnol. Appl. Biochem. 39, 249-255.
17. Encke J, Zu Putlitz J, Geissler M, Wands JR (1998): Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J. Immunol. 161, 4917-4923.
18. Encke J, Zu Putlitz J, Stremmel W, Wands JR (2003): CPG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization. Arch. Virol. 148, 435-448.
19. Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T, Schianchi C, Missale G, Marian MG, Fiaccadori F (1994): T cell response to structural and nonstructural hepatitis C virus antigens in persistent and self limited hepatitis C virus infections. Hepatology 19, 286-295.
20. Forns X, Bukh J, Purcell RH (2002): The challenge of developing a vaccine against hepatitis C virus. J. Hepatol. 37, 686-695.
21. Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushalwar IK, Govindarajan S, Davis HL, Emerson SU, Purcel RH, Bukh J (2000): Vaccination of chimpanizees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32, 618-625
22. Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J (1999): DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellulary and on the cell surface. Vaccine 17, 1992-2002.
23. Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, Muguet S, Depla E, Inchauspe G (2001): Induction of hepatitis C virus E1 envelope protein specific immune response can be enhanced by mutation of N-glycosylation sites. J. Virol. 75, 12088-12097.
24. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr. Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin.Hoffman J, Xu J (2002): Piginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982.
25. Geissler M, Gesien A, Tokushige K, Wands JR (1997): Enhancement of cellular and humoral immune response to hepatitis C virus core protein using DNA based vaccines augmented with cytokine expressing plasmids. J. Immunol. 158, 1231-1237.
26. Ha SJ, Kim DJ, Baek KH, Yun YD, Sung YC (2004): IL-23 induces stronger sustained CTL and Th1 immune responses then IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J. Immunol. 172, 525-531.
27. Hiranuma K, Tamaki S, Nishimura Y, Kusuki S, Isogawa M, Kim G, Kaito M, Kuribayashi K, Adachi Y, Yasutomi Y (1999): Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol. 80, 187-193.
28. Howell C, Jeffers L, Hoofnagle JH (2000): Hepatitis C in African Americans. Summary of a workshop. Gastroenterology 119, 1385-1396.
29. Inchauspe G (1999): DNA vaccine strategies for hepatitis C. J. Hepatol. 30, 339-346.
30. Jiao X, Wang RY, Feng Z, Alter HJ, Shih JW (2003): Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology 37, 452-460.
31. Krieg AM, Davis HL (2001): Enhancing vaccines with immune stimulatory CPG DNA. Curr. Opin. Mol. Ther. 3, 15-24.
32. Lasarte JJ, Corrales FJ, Casares N, Lopez-Diaz DC, Qian C, Xie X, Borras-Cuesta F, Prieto J (1999): Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen. The role of nitric oxide. J. Immunol. 162, 5270-5277.
33. Lechmann M, Liang TJ (2000): Vaccine development for hepatitis C. Semin. Liver Dis. 20, 211-226.
34. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang T (2001): Hepatitis C virus like particles induce virus specific humoral and cellular immune responses in mice. Hepatology 34, 417-423.
35. Lopez-Diaz de Cario A, Casares N, Lasarte JJ, Sarobe P, Perez-Mediavilla LA, Ruiz M, Prieto J, Borras-Cuesta F (1999): Th1 but not Th0 cell help in efficient to induced cytotoxic T lymphocytes by immunization with short synthetic peptides. Int. Immunol. 11, 2025-2033.
36. Lucas M, Tsitoura E, Montoya M, Laliotou B, Aslanoglou E, Kouvatsis V, Entwisle C, Miller J, Klenerman P, Hadziyannis A, Hadziyannis S, Borrow P, Mavromara P (2003): Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus. J. Gen. Virol. 84, 545-554.
37. Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette P, Bukh J, Purcell RH, Devis HL (2002): DNA based vaccination against hepatitis C (HCV): effect of expressing different forms of HCV E2 protein and use of CpG optimized vectors in mice. Vaccine 20, 3263-3271.
38. Makimura M, Miyake S, Akino N, Takamori K, Matsuura Y, Miyamura T, Saito I (1996): Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 14, 28-36.
39. Manns MP, McHutchison JG, Gordan SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001): Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358, 958-965.
40. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, Houghtan M, Fiaccadori F, Ferrari C (1996): Different clinical behaviours of acute hepatitis C virus infection are associated with different vigor of the antiviral cell mediated immune response. J. Clin. Invest. 98, 706-714.
41. Murata K, Lechmann M, Qias M, Gunji T, Liang TJ (2003): Immunization with hepatitis C virus like particles protects mice from recombinant hepatitis C virus vaccinia infection. Proc. Natl. Acad. Sci. USA 100, 6753-6758.
42. Natilla A, Piazzolla G, Nuzzaci M, Saldarelli P, Tortorella C, Antonaci S, Piazzolla P (2004): Cucumber mosaic virus as carrier of a hepatitis C virus derived epitope. Arch. Virol. 149, 137-154.
43. Nemchinov LG, Liang TJ, Rifaat MM, Mazyad HM, Hididi A, Keith JM (2000): Development of a plant derived subunit vaccine candidate against hepatitis C virus. Arch. Virol. 145, 2557-2573.
44. Nishimura Y, Kamei A, Uno-Furuta S, Tamaki S, Kim G, Adachi Y, Kuribayashi K, Matsuura Y, Miyamura T, Yasutomi Y (2000): A single immunization with a plasmid encoding hepatitis C virus (HCV) structural proteins under the elongation factor 1-μ promoter elicits HCV specific cytotoxic T-lymphocytes (CTL). Vaccine 18, 675-680.
45. Pancholi P, Liu Q, Tricoche N, Zhang P, Perkus ME, Prince AM (2000): DNA prime Canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J. Infect. Dis. 182, 18-27.
46. Pancholi P, Perkus M, Tricoche N, Liu Q, Prince AM (2003): DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant Canarypox virus boosting induces immune responses and protection from recombinant HCV vaccinia virus infection in HLA-A2.1-Transgenic mice. J. Virol. 77, 382-390.
47. Qiao M, Murata K, Davis AR, Jeong SH, Liang TJ (2003): Hepatitis C virus like particles combined with novel adjuvant systems enhance virus specific immune responses. Hepatology 37, 52-59.
48. Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM (2000): Recent advances with recombinant bacterial vaccine vectors. Mol. Med. Today 6, 66-71.
49. Shirai M, Chen M, Arichi T, Masaki T, Nishioka M, Newman M, Nakazawa T, Feinstone SM, Berzofsky JA (1996): Use of intrinsic and extrinsic helper epitopes for in vivo induction of antihepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J. Infect. Dis. 173, 24-31.
50. Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, Pomerantz RJ, Schnell MJ (2002): Live and killed rhabdovirus vectors as potential hepatitis C vaccines. Virology 292, 23-24.
51. Uno-Furuta S, Matsuo K, Tamaki S, Takamura S, Kamei A, Kuromatsu I, Kaito M, Matsuura Y, Miyamura T, Adachi Y, Yasutomi Y (2003): Immunization with recombinant Calmette-Guerin bacillus (BCG) hepatitis C virus (HCV) elicits HCV specific cytotoxic T lymphocytes in mice. Vaccine 21, 3149-3156.
52. Wedemeyer H, Gagneten S, Devis A, Bartenschlager R, Feinstone S, Rehermann B (2001): Oral immunization with HCV-NS3 transformed Salmonella: induction of HCV specific CTL in a transgenic mouse model. Gastroenterology 121, 1158-1166.